Englewood Cliffs, NJ, May 25, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has submitted its initial application to list on the NASDAQ Capital Market (“NASDAQ”). The Company previously announced its board approval to begin the process for an up-listing.


Previous articleHealth Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms
Next articleAdding to their Expert Team, Albert Labs Announces the Formation and Chairs of its Two Advisory Boards